Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
Subscribe To Our Newsletter & Stay Updated
